New US tariff measures and acute geopolitical tensions are reshaping the global pharmaceutical landscape, prompting companies to rethink supply chains and production strategies, according to GlobalData.
A key driver is the U.S. administration’s decision to impose tariffs on imported pharmaceuticals and their ingredients, upending decades of medicines trade orthodoxy. The policy introduces a complex system of incentives linked to domestic manufacturing and pricing agreements. At the same time, the strong focus on onshoring highlights the broader push to strengthen US production capacity.
Dominic Tyer, Senior Editor at GlobalData, comments: “The tariff framework fundamentally changes the operating environment for global pharma. While pricing agreements remain relevant, US priorities have been more closely calibrated around onshoring manufacturing, with companies now under even greater pressure to align their production footprints with policy expectations.”
This shift will continue to drive increased investment in US-based manufacturing, building on the tens of billions of dollars that major pharmaceutical companies have already committed to expand their domestic capacities.
The policy is examined in the latest edition of GlobalData’s monthly “Bio/Pharmaceutical Outsourcing” report, which also notes that the current Middle East conflict is adding further strains for pharma manufacturing. Rising energy prices, disrupted logistics routes, and higher freight costs are increasing production expenses and supply chain uncertainty.
Edita Hamzic, Healthcare Analyst at GlobalData, adds: “The current geopolitical environment is intensifying existing vulnerabilities. Supply chains remain highly concentrated and cost sensitive. Even moderate disruptions can have downstream effects on medicine availability and pricing.”
The impact is widespread across regions. The US faces heightened risk due to its dependence on imported generics, and similar vulnerabilities exist in the EU and UK. In Asia-Pacific, energy dependence and currency pressures are increasing production costs.
Hamzic concludes: “The addition of geopolitical tension to the US push to onshore pharma manufacturing will increase pressure on companies to rewire supply chains and production strategies, while also forcing them to evaluate the real-world effects of extraordinary trade policy changes.”
Source: GlobalData